Is New Long‑Acting Atopic Dermatitis Antibody IND Approval Altering The Investment Case For Kelun-Biotech (SEHK:6990)?

Simply Wall St.03-15 23:15

On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619889904?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-15 23:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619889904","market":"nz","top_or_hot":-1,"title":"Is New Long‑Acting Atopic Dermatitis Antibody IND Approval Altering The Investment Case For Kelun-Biotech (SEHK:6990)?","media":"Simply Wall St.","content":"<div>\n<p>On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-new-longacting-atopic-dermatitis-antibody-ind-approval-al\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is New Long‑Acting Atopic Dermatitis Antibody IND Approval Altering The Investment Case For Kelun-Biotech (SEHK:6990)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs New Long‑Acting Atopic Dermatitis Antibody IND Approval Altering The Investment Case For Kelun-Biotech (SEHK:6990)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-15 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-new-longacting-atopic-dermatitis-antibody-ind-approval-al><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-new-longacting-atopic-dermatitis-antibody-ind-approval-al\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-new-longacting-atopic-dermatitis-antibody-ind-approval-al","article_id":"2619889904","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/is-new-longacting-atopic-dermatitis-antibody-ind-approval-al","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619889904","pubTimestamp":1773587737,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-based mechanism and extended half-life enabling subcutaneous dosing.\nThis IND approval highlights Kelun-Biotech’s growing capabilities in innovative biologics and positions SKB575/HBM7575 as a potentially differentiated long-interval therapy candidate in atopic dermatitis.\nWe will now examine...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","06990":"科伦博泰生物-B","XBI":"SPDR S&P Biotech ETF","BK4588":"碎股","IND":"Xtrackers Nifty 500 India ETF","BK1161":"生物科技","BK4585":"ETF&股票定投概念"},"translate_title":"新的长效特应性皮炎抗体IND批准是否会改变科伦生物（SEHK：6990）的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"06990":0.9,"IND":1.5},"content_text":"On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-based mechanism and extended half-life enabling subcutaneous dosing. This IND approval highlights Kelun-Biotech’s growing capabilities in innovative biologics and positions SKB575/HBM7575 as a potentially differentiated long-interval therapy candidate in atopic dermatitis. We will now examine how this long-acting bispecific antibody IND approval could influence Kelun-Biotech’s broader investment narrative in immunology. The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementWhat Is Sichuan Kelun-Biotech Biopharmaceutical's Investment Narrative?To own Kelun-Biotech, you need to believe in its transition from a loss-making, high-valuation biotech into a commercial-stage company underpinned by a broad oncology and immunology pipeline. The stock has pulled back over the past quarter after a strong 1-year run, so near term the key catalysts remain 2025 results on 23 March and continued progress and monetisation around sac-TMT across multiple cancer indications, particularly via the MSD collaboration. The new IND approval for SKB575/HBM7575 adds a fresh immunology angle but is unlikely to shift the short term earnings picture, given its very early stage. Instead, it slightly widens the gap between ambitious growth forecasts and current losses, reinforcing existing risks around execution, high price-to-book and reliance on external partners to share development costs. But there is one execution risk around these partnerships that investors should not ignore.\n\nSichuan Kelun-Biotech Biopharmaceutical's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesSEHK:6990 1-Year Stock Price Chart The Simply Wall St Community currently contributes 1 fair value view, clustering around HK$914.07, while recent SKB575/HBM7575 progress and Kelun-Biotech’s ongoing losses remind you to weigh optimism against clinical and funding risk.Explore another fair value estimate on Sichuan Kelun-Biotech Biopharmaceutical - why the stock might be worth just HK$914.07!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Sichuan Kelun-Biotech Biopharmaceutical research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Sichuan Kelun-Biotech Biopharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sichuan Kelun-Biotech Biopharmaceutical's overall financial health at a glance.Want Some Alternatives?Our daily scans reveal stocks with breakout potential. Don't miss this chance:This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619889904","isCrawlerRequest":true}